Detailed price information for Rapport Therapeutics Inc (RAPP-Q) from The Globe and Mail including charting and trades.

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarte ...

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated ...

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...

For the first time, clinicians have access to a clear, evidence-based roadmap for adjusting antiseizure medication doses ...

The first seizure clinic model enabled rapid diagnosis and treatment for children with epilepsy, according to data presented ...

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, ...

-- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting forthcoming PMA supplement submission -- -- Remains on track to submit NAUTILUS PMA Supplement to ...

“It’s all about the brain,” said Jennifer DeWolfe, D.O., professor in the UAB Department of Neurology. “Seizure manifestations are stereotyped, so the same symptoms occur with each seizure that ...

Children referred to a first seizure clinic (FSC) see a neurologist epilepsy specialist within one week, according to a study presented at the annual meeting of the American Epilepsy Society, held ...

Sign up for TPR Today, Texas Public Radio's newsletter that brings our top stories to your inbox each morning. One in 10 people is affected by seizures. A seizure ...